PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 

Aciont Inc.

Press Releases

Click on the press release below to view it in its entirety

Receive press releases from Aciont Inc.: By Email RSS Feeds:
Aciont was issued a U.S. patent that covers an important aspect of the novel design of its main Visulex ocular drug delivery system which has been tested for safety and efficacy in its lead clinical program under U.S. IND. - October 12, 2019
Aciont Inc. announced today that data from the clinical study of the DSP-Visulex technology is published online ahead of print in Current Eye Research. Reference: Papangkorn K, Truett KR, Vitale AT, Jhaveri C, Scales DK, Foster CS, Montieth A, Higuchi JW, Brar B, Higuchi WI. Novel dexamethasone sodium phosphate treatment (DSP-Visulex) for noninfectious anterior uveitis: a randomized phase I/II clinical trial. Current Eye Research. - December 06, 2018
Aciont Inc. announced today that Dr. Kongnara Papangkorn, VP of Product Development, will be presenting clinical data of Aciont’s lead product, DSP-Visulex, from its phase 1/2 clinical trial in the treatment of noninfectious anterior uveitis (DSPV-201) at the Association for Research in Vision... - March 10, 2018
Aciont Inc. announced today that both Kongnara Papangkorn, Research Director and Sarah Abdulla Molokhia, Scientific Research Consultant, will present on Aciont’s Visulex technologies at the Global Technology Community’s 4th Ocular & Drug Discovery Conference, February 27-28, 2012, in... - January 12, 2012
Dr. Kongnara Papangkorn’s presentation is entitled, “Safety Aspects and Drug Delivery Performance of Visulex® Passive Delivery System” - June 09, 2011
John Higuchi will present on behalf of Aciont Inc at the IN3 West Medical Device Conference in Las Vegas, NV on February 22, 2011. - February 10, 2011
Aciont Inc. announced today that it has been awarded $488,958 to support two projects under the U.S. Government’s Qualifying Therapeutic Discovery Project (QTDP) program. Aciont submitted only the following two applications to the program of which both were funded at the maximum allocation amount: “Iontophoretic... - November 05, 2010
Aciont is awarded a phase I SBIR $214K grant for the project titled “Novel Method for the Ocular Iontophoretic Delivery of Avastin® and Lucentis®.” - July 08, 2010
The National Eye Institute (NEI) awarded a $2.18 million grant to Aciont Inc. to help fund its development of a non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis. - December 12, 2009
Press Releases 1 - 9 of 9 Page: 1
Promote Your Business